天津医药

天津医药 ›› 2018, Vol. 46 ›› Issue (10): 1131-1134.doi: 10.11958/20180786

• 综述 • 上一篇    下一篇

微小RNA在免疫性血小板减少症发病机制中的研究进展

赵海丰，阚育田，王鑫源，张翼鷟△   

  1. 基金项目：国家自然科学基金资助项目（81100337，81470283，81570201） 作者单位：天津医科大学肿瘤医院，国家肿瘤临床医学研究中心，天津市“肿瘤防治”重点实验室，天津市恶性肿瘤临床医学研究中心（邮 编300060） 作者简介：赵海丰（1980），男，博士，副主任医师，副教授，主要从事ITP发病机制的研究 △通讯作者 E-mail: yizhuozhang111@163.com
  • 收稿日期:2018-05-15 修回日期:2018-07-15 出版日期:2018-10-15 发布日期:2018-11-09
  • 通讯作者: 张翼鷟 E-mail:aprilzyz@yahoo.com
  • 基金资助:
    miR-409-3p 在ITP Th1/Th2 失衡中的作用及机制研究;组蛋白乙酰化修饰在ITP发病中的作用及机制研究;BCR信号通路和c-Myc在肿瘤微环境介导的弥漫大B细胞淋巴瘤化疗耐药中 的协同作用研究

The progress of miRNA in the pathogenesis of immune thrombocytopenia

ZHAO Hai-feng, KAN Yu-tian, WANG Xin-yuan, ZHANG Yi-zhuo△   

  1. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin Clinical Research Center for Cancer, Tianjin 300060, China △Corresponding Author E-mail: yizhuozhang111@163.com
  • Received:2018-05-15 Revised:2018-07-15 Published:2018-10-15 Online:2018-11-09

PDF (PC)

3518

摘要： 摘要：免疫性血小板减少症（ITP）是由于血小板破坏增加或生成减少导致外周血血小板的减少，引起皮肤、黏膜 及内脏出血等临床表现为特点的常见出血性疾病。ITP的发病机制迄今为止尚未得到完全阐明，积极探索本病的发 病机制，不仅具有重要的理论意义，而且可能为本病的治疗提供新的策略。微小RNA（microRNA，miRNA）是一类长 度约为19~22个核苷酸的小分子非编码RNA，通过调控其靶基因，参与多种疾病的发生和发展。目前miRNA在ITP 发病机制中的研究越来越广泛，本文就近年来针对miRNA在ITP发病机制中的研究进展做一综述。

关键词: 血小板减少, 微RNAs, 免疫性血小板减少症, 综述

Abstract: Abstract：Immune thrombocytopenia (ITP), one of the most common bleeding disorders, is characterized by clinical manifestations of skin mucosa and internal bleeding and by decreased platelet count due to auto-antibody mediating the platelets destruction and insufficient platelet production. The exact etiology of ITP is still unclear so far. To fully understand the pathogenesis of ITP not only has important theoretical significance but also may provide a new strategy for the treatment of the disease. MicroRNA (miRNA) is a class of small non-coding RNAs with a length of 19-22 nucleotides. It is involved in the occurrence and development of many diseases by regulating its target genes. At present, there are more and more studies on the role of microRNAs in the pathogenesis of ITP. In this review, the progress of miRNA in the pathogenesis of ITP in recent years was summarized

Key words: thrombocytopenia, MicroRNAs, immune thrombocytopenia, review